Clascoterone 1% Cream for Acne Treatment
Apply clascoterone 1% cream twice daily (morning and evening) as a thin layer to affected areas in patients ≥12 years of age with mild-to-moderate acne vulgaris. 1
Application Instructions
Dosing regimen: Apply approximately 1 gram (a thin layer) to the affected area twice daily 1. For facial application, use a pea-sized amount for each area of the face (forehead, chin, and each cheek) 1.
Timing: Apply in the morning and evening after gently washing the skin 1.
Important restrictions:
Efficacy Profile
Clascoterone is the first FDA-approved topical androgen receptor inhibitor for acne, representing a novel mechanism of action 2, 1. The 2024 AAD guidelines provide a conditional recommendation for topical clascoterone in acne management 2.
Clinical trial results:
- Treatment success rates (IGA score of clear/almost clear with ≥2-grade improvement) at 12 weeks: 16.4% in adolescents and 23.3% in adults versus 3.9% and 9.4% with vehicle, respectively 3
- Significant reductions in inflammatory lesions (54%) and non-inflammatory lesions (34%) at 12 weeks 4
- 27% reduction in sebum production at 12 weeks 4
- Efficacy sustained up to 12 months with continued treatment 5
Patient Selection
Approved for: Patients ≥12 years of age with acne vulgaris 1
Efficacy is independent of sex: Both male and female patients show significant benefit, with no clinically meaningful differences in response between sexes 3. This is particularly notable as clascoterone is the first topical antiandrogen approved for both male and female patients 5.
Age considerations: While efficacy is demonstrated in both adolescents and adults, some data suggest greater lesion count reductions in adults, though this requires further confirmation 3, 5.
Safety and Tolerability
Common adverse effects (7-12% of patients): 1
- Erythema/reddening
- Pruritus
- Scaling/dryness
- Edema, stinging, and burning (>3% but similar to vehicle)
These local reactions are typically mild and transient 5. If significant irritation occurs, discontinue or reduce application frequency 1.
Important safety considerations:
HPA axis suppression: Observed in 5% of adults and 9% of adolescents after 2 weeks of treatment, but all subjects returned to normal function 4 weeks after stopping treatment 1. Pediatric patients may be more susceptible to systemic effects 1
Hyperkalemia: Shifts from normal to elevated potassium occurred in 5% of clascoterone-treated subjects (4% with vehicle) 1
No contraindications listed 1
Pregnancy category not specified in current labeling (drug approved 2020, after pregnancy category system discontinued)
Combination Therapy Considerations
The 2024 AAD guidelines emphasize combining topical therapies with multiple mechanisms of action as a good practice statement 2. While clascoterone can be used as monotherapy, consider combining with:
- Topical retinoids for comedonal components 6
- Benzoyl peroxide (though note that concomitant application may cause orange-brown skin discoloration that can be washed off) 6
Avoid combining with other potentially irritating topical products initially, as clascoterone can induce local irritation 6.
Duration of Treatment
Continue treatment as needed for acne control. If no improvement after 12 weeks, reassess the treatment plan 6. Long-term safety data support use up to 12 months 5.
Clinical Positioning
Clascoterone offers a unique mechanism targeting androgen receptors locally without systemic hormonal effects, making it suitable for both male and female patients who cannot use or prefer to avoid systemic hormonal therapies 5, 7. It represents a valuable addition to the acne treatment armamentarium, particularly for patients seeking alternatives to systemic antiandrogens or those with contraindications to oral therapies.